Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 2—February 2019
Online Report

Public Health–Driven Research and Innovation for Next-Generation Influenza Vaccines, European Union

Adoración Navarro-TornéComments to Author , Finnian Hanrahan, Barbara Kerstiëns, Pilar Aguar, and Line Matthiessen
Author affiliations: European Commission Directorate-General for Research and Innovation, Brussels, Belgium

Main Article

Figure

Funding from the seventh Framework Programme for Research and Technological Development of the European Union (FP7) to influenza vaccine development. MVA, modified vaccinia virus Ankara; VLP, virus-like particle.

Figure. Funding from the seventh Framework Programme for Research and Technological Development of the European Union to influenza vaccine development. EU, European Union; MVA, modified vaccinia virus Ankara; VLP, virus-like particle.

Main Article

Page created: January 18, 2019
Page updated: January 18, 2019
Page reviewed: January 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external